OBJECTIVES: To analyze pulse pressure (PP) as a risk predictor for coronary heart disease (CHD), stroke and cardiovascular disease (CVD; CHD and/or stroke) in type 2 diabetic patients. METHODS: A total of 11,128 female and male type 2 diabetic patients with known baseline PP values and no CVD, aged 50-74 years, were followed for a mean duration of 5.6 years (1998-2003). A subgroup of 5521 patients with known mean PP values (mean values at baseline and at the end of the study) was also included. RESULTS: Hazard ratios (HRs) with 95% CI for fatal/nonfatal CHD with baseline or mean PP>or=75mmHg, compared to <75mmHg, were 1.23 (1.07-1.40; P=0.003) and 1.32 (1.07-1.62; P=0.009), respectively, after adjusting for mean blood pressure (MBP), age, gender, diabetes duration, HbA(1c), body mass index (BMI), lipid-reducing drugs, microalbuminuria > 20microg/min, antihypertensive drugs and hypoglycaemic treatment, using Cox regression analyses. Fully-adjusted respective HRs for stroke were 1.17 (0.98-1.39) and 1.21 (0.90-1.61) and, for CVD, 1.23 (1.10-1.37; P<0.001) and 1.28 (1.07-1.52; P=0.007). Fully-adjusted HRs for baseline PP increased per quartile and, CHD, stroke or CVD, were 1.09 (1.03-1.16; P=0.004), 1.14 (1.05-1.23; P=0.002) and 1.11 (1.05-1.17; P<0.001), respectively. The data suggest that, if a mean PP>or=75mmHg were to be avoided, then 15% and 17% of CHD and or CVD, cases, respectively, in such a cohort might be prevented after multivariable adjustments, with a further 10% of cases avoided if also adjusted for MBP and age. Increasing baseline MBP, age and microalbuminuria were independently and significantly associated (P<0.001) with increasing baseline or mean PP. CONCLUSION: Increased PP is a powerful independent risk predictor of CVD in type 2 diabetic patients, and lowering PP can lead to a marked reduction in risk.
OBJECTIVES: To analyze pulse pressure (PP) as a risk predictor for coronary heart disease (CHD), stroke and cardiovascular disease (CVD; CHD and/or stroke) in type 2 diabeticpatients. METHODS: A total of 11,128 female and male type 2 diabeticpatients with known baseline PP values and no CVD, aged 50-74 years, were followed for a mean duration of 5.6 years (1998-2003). A subgroup of 5521 patients with known mean PP values (mean values at baseline and at the end of the study) was also included. RESULTS: Hazard ratios (HRs) with 95% CI for fatal/nonfatal CHD with baseline or mean PP>or=75mmHg, compared to <75mmHg, were 1.23 (1.07-1.40; P=0.003) and 1.32 (1.07-1.62; P=0.009), respectively, after adjusting for mean blood pressure (MBP), age, gender, diabetes duration, HbA(1c), body mass index (BMI), lipid-reducing drugs, microalbuminuria > 20microg/min, antihypertensive drugs and hypoglycaemic treatment, using Cox regression analyses. Fully-adjusted respective HRs for stroke were 1.17 (0.98-1.39) and 1.21 (0.90-1.61) and, for CVD, 1.23 (1.10-1.37; P<0.001) and 1.28 (1.07-1.52; P=0.007). Fully-adjusted HRs for baseline PP increased per quartile and, CHD, stroke or CVD, were 1.09 (1.03-1.16; P=0.004), 1.14 (1.05-1.23; P=0.002) and 1.11 (1.05-1.17; P<0.001), respectively. The data suggest that, if a mean PP>or=75mmHg were to be avoided, then 15% and 17% of CHD and or CVD, cases, respectively, in such a cohort might be prevented after multivariable adjustments, with a further 10% of cases avoided if also adjusted for MBP and age. Increasing baseline MBP, age and microalbuminuria were independently and significantly associated (P<0.001) with increasing baseline or mean PP. CONCLUSION: Increased PP is a powerful independent risk predictor of CVD in type 2 diabeticpatients, and lowering PP can lead to a marked reduction in risk.
Authors: Kunihiko Aizawa; Francesco Casanova; Phillip E Gates; David M Mawson; Kim M Gooding; W David Strain; Gerd Östling; Jan Nilsson; Faisel Khan; Helen M Colhoun; Carlo Palombo; Kim H Parker; Angela C Shore; Alun D Hughes Journal: Hypertension Date: 2021-06-01 Impact factor: 10.190
Authors: Michael Pfeifer; Raymond R Townsend; Michael J Davies; Ujjwala Vijapurkar; Jimmy Ren Journal: Cardiovasc Diabetol Date: 2017-02-27 Impact factor: 9.951
Authors: Julio A Chirinos; Patrick Segers; Thierry C Gillebert; Marc L De Buyzere; Caroline M Van Daele; Zubair A Khan; Umair Khawar; Dirk De Bacquer; Ernst R Rietzschel Journal: Diabetes Care Date: 2013-04-22 Impact factor: 19.112
Authors: Deborah A Chyun; Frans J Th Wackers; Silvio E Inzucchi; Powell Jose; Curtis Weiss; Janice A Davey; Gary V Heller; Ami E Iskandrian; Lawrence H Young Journal: SAGE Open Med Date: 2015-02-24
Authors: Rizna Abdul Cader; Halim Abdul Gafor; Rozita Mohd; Suriani Ibrahim; W H Wan Haslina; Arba'iyah Bain; Norella Ct Kong Journal: EXCLI J Date: 2012-03-28 Impact factor: 4.068
Authors: R Chilton; I Tikkanen; C P Cannon; S Crowe; H J Woerle; U C Broedl; O E Johansen Journal: Diabetes Obes Metab Date: 2015-10-09 Impact factor: 6.577